Navigation Links
Cancer Research UK Signs Deal With Centella Therapeutics, Inc. to Launch Clinical Development of Radiotherapy-Enhancing Drug
Date:5/25/2011

Cancer Research UK, one of the largest independent funders of cancer research in the world.  CRT's discovery laboratories build on exploratory research to create attractive commercial opportunities through collaboration with research institutes worldwide. Therapeutic programmes are then out-licensed for further development following identification of a suitable partner.

For more information visit www.cancertechnology.co.uk

About Cancer Research UK's Drug Development OfficeCancer Research UK has an impressive record of developing novel treatments for cancer. It currently has a portfolio of around 36 new anti-cancer agents in preclinical development, phase I or early phase II clinical trials. Since 1982, the Cancer Research UK Drug Development Office has taken over 100 potential new anti-cancer agents into clinical trials in patients, five of which have made it to market and many others are still in clinical development. These include Temozolomide, a drug discovered by Cancer Research UK scientists, that is an effective new treatment for brain cancer. Six other drugs are in late development phase III trials. This rate of success is comparable to that of any pharmaceutical company.

About Centella TherapeuticsCentella Therapeutics, Inc. is a wholly owned subsidiary of Varian Medical Systems, Inc. (NYSE: VAR). Varian, headquartered globally in Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy. Centella, which was previously known as Centella biotechnologies, inc., is a dedicated enterprise focused on discovery and development of cancer treatments at the intersection of radiotherapy and pharmaceutical therapeutics.   Centella's mission is to develop a portfolio of drugs with a focus on enhancing the effectiveness of radiotherapy, making Centella the first Radiation Oncology Bi
'/>"/>

SOURCE Varian Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... New York , August 4, 2015 ... report titled " Non-invasive Prenatal Testing (NIPT) Market (BambniTest, ... and Others) - Global Industry Analysis, Size, Volume, Share, ... According to a new market report published by ... Global Industry Analysis, Size, Volume, Share, Growth, Trends and ...
(Date:8/4/2015)... BioElectronics Corporation (OTC Pink: BIEL), the ... medical devices, announced today that its registry study ... device has been published in the prominent peer ... http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More than 5,000 chronic pain sufferers ... Chronic pain is a major ...
(Date:8/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/nl392k/alcohol ) has announced the ... (Household & Personal Care, Pharmaceutical, Oilfield, Agrochemicals, and Others) ... report to their offering. The market ... in 2014 and is projected to grow at a ... data mentioned in the report is based on the ...
Breaking Medicine Technology:Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 2Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 3Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 4Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 5BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2Global Alcohol Ethoxylate Market 2015 - Market Trends, Forecasts to 2019 for the $5.1 Billion Industry 2Global Alcohol Ethoxylate Market 2015 - Market Trends, Forecasts to 2019 for the $5.1 Billion Industry 3
... America,s Specialty Medicines Companies (ASMC), an informal working group ... concerns about H.R. 3962, the "Affordable Health Care for ... These smaller companies fear that the cumulative effect of ... their efforts to bring new medicines to market. ...
... Nov. 6 NuVasive, Inc. (Nasdaq: NUVA ), ... minimally disruptive surgical treatments for the spine, announced today ... President and Chief Financial Officer, effective November 9, 2009. ... Team updates. , "Michael will be an excellent complement ...
Cached Medicine Technology:Statement of America's Specialty Medicines Companies On House Health Care Bill (H.R. 3962) 2NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 2NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 3NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 4NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 5
(Date:8/4/2015)... Denver, CO (PRWEB) , ... August 04, 2015 ... ... for skilled nursing homes and other long-term care facilities, today announced details of ... (QAPI) for nursing homes and centers. , Providigm’s QAPI Accreditation program , ...
(Date:8/4/2015)... ... August 04, 2015 , ... A new report by ... reseller channel will grow at least 6 percent in 2015, as solution providers ... greater than their OEM/vendor partners. , The 2112 Group’s 2015 Midyear Channel ...
(Date:8/4/2015)... ... August 04, 2015 , ... Driving skills ... end to driving, says the August 2015 Harvard Health Letter. , "Age and ... It requires an individual assessment of skills," says Lissa Kapust, a social worker ...
(Date:8/4/2015)... ... , ... Updated enrollment data on the top U.S. health plans, as collected ... http://www.AISHealth.com . The data is free to all registered users to AISHealth.com. Based ... on the website’s “Data” section include:, , Top 25 U.S. ...
(Date:8/4/2015)... CA (PRWEB) , ... August 04, 2015 , ... The ... designed to treat Retinitis pigmentosa, a rare eye disease that progressively causes blindness, were ... Academy of Ophthalmology. According to the results of the trial, the implant, more commonly ...
Breaking Medicine News(10 mins):Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 2Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 3Health News:The 2112 Group Forecasts North America IT Channel to Grow At Least 6% in 2015 2Health News:The 2112 Group Forecasts North America IT Channel to Grow At Least 6% in 2015 3Health News:Assessment Can Help Older Drivers Keep Driving Safely, from the August 2015 Harvard Health Letter 2Health News:Atlantic Information Services Website Offers Up-to-Date U.S. Health Plan Enrollment Data 2Health News:“Bionic Eye” Implant for the Blind Proved Safe and Effective at the End of a Three Year Clinical Trial 2
... In March, AHIP,s Board of,Directors advocated for ... and Medicare Part D plan marketing activities. Today,the ... new regulations., (Logo: http://www.newscom.com/cgi-bin/prnh/20040830/AHIPLOGO ), ... beneficiaries can rely on the,information being provided to ...
... countless years of collective brainpower to rescuing princesses or ... at the University of Washington will try to harness ... even finding a cure for HIV., A new game, ... Introductory levels teach the rules, which are the same ...
... DALLAS, May 8 May has been designated Allergy ... working to educate,Americans about the conditions. Of most importance ... but especially when the environment indoors or,outdoors may trigger ... 3,800 asthma-related deaths in the,United States. The American Association ...
... Software training supplements counseling, could also treat other ... -- The use of a computer-assisted training program, ... stay abstinent longer than counseling alone, a Yale ... , The trial included 77 people who sought ...
... Calif., May 8 As injectable fillers,become mainstream ... longer lasting,and less expensive alternatives to prevent facial ... busy practice in,Beverly Hills says, "Fillers such as ... suture material. When injected into,human tissue, all of ...
... May 8 Metametrix Clinical Laboratory (, ... and metabolic testing,announced the introduction of the ... the oxidative products of,tetrahydrobiopterin (BH4)., Neopterin ... reactions,involving tetrahydrobiopterin (BH4). Restricted BH4 availability has ...
Cached Medicine News:Health News:Computer game's high score could earn the Nobel Prize in medicine 2Health News:Computer game's high score could earn the Nobel Prize in medicine 3Health News:Computer game's high score could earn the Nobel Prize in medicine 4Health News:Respiratory Therapists Offer Breath of Fresh Air During Allergy & Asthma Month 2Health News:Computer Program Helps Drug Abusers Stay Clean 2Health News:Dr. Arnold Klein Warns of Dangers With Permanent and Longer Lasting Injectable Fillers 2Health News:Metametrix Introduces the New Neopterin/Biopterin Profile 2
Bacterial/Viral Filters for Anesthesia and Respiratory Applications...
Bacterial/Viral Filters for Anesthesia and Respiratory Applications...
Indications For Usage: ,Single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to be replaced at least once every 24 hours....
... T helps provide protection to the exposed airway ... extremely lightweight making it ideal for active young ... rate of heat and moisture recovery, it ensures ... HMEs and filters have ISO standard tapered ends ...
Medicine Products: